Stem Cell Sector Overview - November 5, 2019

BioInformant has released exciting new coverage of the Stem Cell Sector, including industry updates, announcements, events and interviews. Explore it below and let me know what you think?

FUJIFILM Irvine Scientific Announces Construction of a New Cell Culture Media Manufacturing Site in Europe

FUJIFILM Irvine Scientific, Inc., a global leader in the innovation, development, and manufacture of cell culture media, announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this project demonstrates its commitment to accelerate development in bioproduction, and cell and gene therapy markets.

6th Perinatal Stem Cell Society Congress, March 5-6, 2020 (Salt Lake City, UT)

Hosted by the Perinatal Stem Cell Society, this two-day event will feature the world’s leading perinatal stem cell researchers, specializing in Amnion, Amniotic Fluid, Cord Blood for Regenerative Medicine, Cord Tissue, and the Placenta. Its scientific program will cover all aspects of the perinatal stem cell field, with opportunities to learn from leading clinicians utilizing cellular therapies within their practices. Click here to learn more or register.

Behind the Scenes at FUJIFILM Irvine Scientific (FISI) with Yutaka Yamaguchi (President)

FUJIFILM Irvine Scientific (FISI) is the world’s leading manufacturer of cell culture media, reagents, and medical devices that are used across the cell therapy, regenerative medicine, assisted reproductive technology, and industrial cell culture markets. In this interview with Yutaka Yamaguchi, President of FISI, we explore the acquisition of Irvine Scientific, the importance of the company’s dual manufacturing facilities, traits that differentiate FISI from its competitors, and more.

CARsgen’s CAR-T Therapy CT053 for R/R Multiple Myeloma is 37th Publicly Announced RMAT

CARsgen Therapeutics Co. Ltd., a clinical-stage biopharmaceutical company announced that the United States Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational CT053 CAR-T cell therapy. CT053 is a fully human anti-BCMA (B Cell Maturation Antigen) autologous chimeric antigen receptor (CAR) T Cell therapy for the treatment of relapsed and/or refractory multiple myeloma (rrMM).

What is an RMAT and Who Has One? | List of 37 RMAT Designations

The list of publicly announced RMAT’s has risen to 37. However, the U.S. FDA states it has received 115 total requests for RMAT designations and granted 44. This means that slightly over one-third of RMAT applications get approved. CARsgen Therapeutics’ chimeric antigen receptor T-cell therapy (CT053) for patients with relapsed or refractory multiple myeloma was the most recent addition on October 28, 2019.

Stemmatters, a Portuguese Integrated Therapeutics Developer and Cell Therapy CDMO

Stemmatters is a Portuguese CDMO organisation based in Barco, Guimarães. Originally a spin-off from University of Minho, it offers contract development and manufacturing services for cell-based advanced therapies, exosomes, blood-derived biologics, tissue products, biomaterials, and combination devices. In this interview, we explore Stemmatters' history, services, manufacturing facilities, and future goals.

Synthego Launches High-Throughput iPS Cell Genome Engineering

Synthego, the leading genome engineering company, has announced the launch of genome engineering for induced pluripotent stem (iPS) cells. The new offering expands Synthego’s automated cell editing to achieve unprecedented editing efficiency of iPS cells at an industrial scale.

RoosterBio Launches the Only Umbilical Cord hMSC System in the World Designed for Perinatal Cell Therapy Product Development

RoosterBio, Inc, a biotechnology market disrupter and leading supplier of innovative human mesenchymal stem/stromal cell (hMSC) biomanufacturing systems, released the Regenerative Medicine industry’s first human umbilical cord (hUC) MSC paired cell and media system designed for product development and bringing with it an unprecedented step-change in quantifiable productivity metrics.

How NanoCellect is Revolutionizing Cell Analysis and Sorting for Stem Cells (and Other Fragile Samples)

NanoCellect® is a biotechnology company that facilitates breakthrough biomedical discoveries through cutting-edge cell analysis and sorting technology. Delivering sterile, portable, intuitive solutions for sorting fragile samples (such as stem cells), NanoCellect is pushing the status quo of flow cytometry to empower biomedical scientists with higher viability cells, minimal risk of sample-to-sample contamination, and efficient workflows.

Platelet BioGenesis Bags $56M to Develop Human iPSC-Derived Platelets as Nuclear Countermeasure

Founded in 2014 in Cambridge, Massachusetts, Platelet BioGenesis is a biotechnology company that has developed the world’s first technology capable of producing human platelets (PLTs+™) from human induced pluripotent stem cells (iPSCs). For the first time in history, the process could make platelet donation donor-independent.

Fate Therapeutics Announces the Opening of its cGMP Manufacturing Facility Dedicated to iPSC-derived Cell Therapies

Fate Therapeutics, Inc. (FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced that the Company has opened its current Good Manufacturing Process (cGMP) compliant manufacturing facility for the clinical production of its off-the-shelf natural killer (NK) cell and chimeric antigen receptor (CAR) T-cell product candidates.

Positive Study Results of Phase IIa Clinical Trial Using IV Administered MSCs for Ischemic Stroke Published in Peer-Reviewed Stroke Journal

Results from a study sponsored by Stemedica Cell Technologies, Inc., a global biotechnology company that uses allogeneic stem cells for ischemic conditions, form the basis for a peer-reviewed paper published in Stroke entitled “Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke.”

Phacilitate Leaders World (Part of Advanced Therapy Week) and the World Stem Cell Summit (Jan 21-24, 2020)

Phacilitate Leaders World, now part of Advanced Therapies Week, and the World Stem Cell Summit (WSCS), will be co-hosted in Miami, FL, from January 21-24, 2020. Bringing together the entire advanced therapies ecosystem, this is the largest international conference and networking event of the year. If you're ready to join the rest of your industry peers, you can receive 10% off your delegate pass or sponsorship using the code: BIOINFORMANT.

About BioInformant

As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.